{"id":"allogeneic-bone-marrow-transplantation","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Graft-versus-host disease (acute)"},{"rate":"30-60","effect":"Graft-versus-host disease (chronic)"},{"rate":"40-60","effect":"Infection"},{"rate":"40-80","effect":"Mucositis"},{"rate":"5-20","effect":"Hepatic veno-occlusive disease"},{"rate":"5-15","effect":"Graft failure or rejection"},{"rate":"5-10","effect":"Secondary malignancy"}]},"_chembl":{"chemblId":"CHEMBL6068575","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The procedure involves myeloablative or reduced-intensity conditioning to eliminate diseased marrow, followed by infusion of donor-derived hematopoietic stem cells that engraft and reconstitute hematopoiesis. This approach is used to treat hematologic malignancies, severe aplastic anemia, and certain genetic disorders, with therapeutic benefit derived from both the replacement of defective marrow and the graft-versus-tumor/disease effect from donor immune cells.","oneSentence":"Allogeneic bone marrow transplantation replaces a patient's diseased or damaged bone marrow with healthy hematopoietic stem cells from a matched donor to restore normal blood cell production and immune function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:50.964Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Allotransplantation","title":"Allotransplantation","extract":"Allotransplant is the transplantation of cells, tissues, or organs to a recipient from a genetically non-identical donor of the same species. The transplant is called an allograft, allogeneic transplant, or homograft. Most human tissue and organ transplants are allografts."},"indications":{"approved":[{"name":"Acute myeloid leukemia"},{"name":"Acute lymphoblastic leukemia"},{"name":"Chronic myeloid leukemia"},{"name":"Myelodysplastic syndrome"},{"name":"Severe aplastic anemia"},{"name":"Lymphoma"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases","enrollment":354},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT00001529","phase":"","title":"Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1996-03-18","conditions":"Graft-Versus-Host Disease, Graft-versus-leukemia, Donor Apheresis","enrollment":500},{"nctId":"NCT07498465","phase":"PHASE1","title":"A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-09-10","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT00576979","phase":"PHASE1, PHASE2","title":"Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-03-04","conditions":"Leukemia","enrollment":51},{"nctId":"NCT04742634","phase":"PHASE1, PHASE2","title":"Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-05-12","conditions":"Myelodysplastic Syndromes","enrollment":209},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT01315132","phase":"PHASE2","title":"A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2008-04-10","conditions":"Hematological Malignancies, Leukemia, Lymphoma","enrollment":47},{"nctId":"NCT05796570","phase":"PHASE2","title":"A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies","status":"RECRUITING","sponsor":"Franziska Wachter","startDate":"2023-04-19","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies","enrollment":37},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT04282187","phase":"PHASE2","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-03-24","conditions":"Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome","enrollment":25},{"nctId":"NCT04579523","phase":"PHASE1","title":"²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-06-01","conditions":"Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT03980769","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-05","conditions":"Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder","enrollment":40},{"nctId":"NCT06856226","phase":"","title":"Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-04","conditions":"Leukemia, Lymphoma, Hematologic Malignancy","enrollment":88},{"nctId":"NCT07457866","phase":"NA","title":"Rehab Study for alloBMT Patients","status":"RECRUITING","sponsor":"Jennifer Jones","startDate":"2025-10-01","conditions":"Allogenic Bone Marrow Transplantation","enrollment":208},{"nctId":"NCT04965597","phase":"PHASE2","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-04-19","conditions":"Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia","enrollment":40},{"nctId":"NCT04384692","phase":"PHASE2","title":"Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-18","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":53},{"nctId":"NCT06508138","phase":"PHASE1","title":"Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection","status":"ENROLLING_BY_INVITATION","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-18","conditions":"HPV 16 Infection, HPV-Related Carcinoma, Recurrence","enrollment":24},{"nctId":"NCT07225985","phase":"PHASE1, PHASE2","title":"Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-05-01","conditions":"Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma","enrollment":50},{"nctId":"NCT07455500","phase":"NA","title":"Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic Syndromes (MDS","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2026-05","conditions":"Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT06575296","phase":"PHASE1","title":"Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-12-06","conditions":"Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia","enrollment":27},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT06498973","phase":"PHASE1","title":"Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-01-28","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":43},{"nctId":"NCT04713046","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-18","conditions":"HPV 16+ Recurrent or Metastatic Cancer","enrollment":24},{"nctId":"NCT02333162","phase":"PHASE1","title":"Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2014-12-05","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT07044544","phase":"PHASE1","title":"Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07148947","phase":"PHASE2","title":"Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-03-02","conditions":"Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm","enrollment":27},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT04195633","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-01-25","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT05470491","phase":"PHASE1, PHASE2","title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-26","conditions":"HIV, Hematologic Malignancies","enrollment":265},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT05589896","phase":"PHASE1, PHASE2","title":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Ossium Health, Inc.","startDate":"2024-08-16","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT05170828","phase":"PHASE1","title":"Cryopreserved MMUD BM With PTCy for Hematologic Malignancies","status":"WITHDRAWN","sponsor":"Ossium Health, Inc.","startDate":"2022-09","conditions":"Acute Leukemia, Myelodysplastic Syndromes, T-lymphoblastic Lymphoma","enrollment":""},{"nctId":"NCT07216443","phase":"PHASE2","title":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2025-12-09","conditions":"Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia","enrollment":80},{"nctId":"NCT03394365","phase":"PHASE3","title":"A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2017-12-29","conditions":"Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders","enrollment":115},{"nctId":"NCT05017545","phase":"PHASE1, PHASE2","title":"Carfilzomib and Belatacept for Desensitization","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-28","conditions":"Highly Sensitized Prospective Kidney Transplant Recipients","enrollment":21},{"nctId":"NCT06995521","phase":"PHASE2","title":"Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population","status":"NOT_YET_RECRUITING","sponsor":"Sung Won Choi","startDate":"2026-03","conditions":"GVHD","enrollment":55},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":50},{"nctId":"NCT01203722","phase":"PHASE1, PHASE2","title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-09","conditions":"Hematologic Malignancies","enrollment":87},{"nctId":"NCT07408583","phase":"PHASE1, PHASE2","title":"Prenatal Transplantation for Fetuses With Fanconi Anemia","status":"NOT_YET_RECRUITING","sponsor":"Agnieszka Czechowicz","startDate":"2026-07","conditions":"Fanconi Anemia, Anemia, Hypoplastic, Congenital, Congenital Bone Marrow Failure Syndromes","enrollment":12},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT05393804","phase":"PHASE2","title":"A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-05-20","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT03467386","phase":"PHASE1","title":"Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2018-03-19","conditions":"Acute Myeloid Leukemia","enrollment":56},{"nctId":"NCT04328714","phase":"PHASE1","title":"Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease","status":"TERMINATED","sponsor":"Edwin Horwitz","startDate":"2021-12-02","conditions":"Acute Leukemia, Myelodysplastic Syndromes","enrollment":4},{"nctId":"NCT07407660","phase":"PHASE3","title":"Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-02-01","conditions":"Acute Myeloid Leukemia","enrollment":250},{"nctId":"NCT04368559","phase":"PHASE3","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mundipharma Research Limited","startDate":"2020-05-11","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":602},{"nctId":"NCT06590285","phase":"NA","title":"Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation","status":"RECRUITING","sponsor":"Scripps Health","startDate":"2026-03-01","conditions":"GVHD, Bone Marrow Transplant Complications","enrollment":60},{"nctId":"NCT06492707","phase":"PHASE1","title":"DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial","status":"SUSPENDED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-23","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT02891603","phase":"PHASE1, PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":"Graft Vs Host Disease, GVHD","enrollment":40},{"nctId":"NCT00071045","phase":"","title":"Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2003-10-08","conditions":"Neoplasms, Hematologic Neoplasms, Healthy Volunteers","enrollment":6000},{"nctId":"NCT07046078","phase":"PHASE2","title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-26","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":20},{"nctId":"NCT06752577","phase":"","title":"Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-12-22","conditions":"Chronic Kidney Diseases, Kidney Transplant","enrollment":75},{"nctId":"NCT03842696","phase":"PHASE1, PHASE2","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-02-04","conditions":"Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":43},{"nctId":"NCT04217356","phase":"","title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-05","conditions":"Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer","enrollment":90},{"nctId":"NCT04994808","phase":"PHASE2","title":"Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-08-11","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":23},{"nctId":"NCT04959175","phase":"PHASE1, PHASE2","title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-23","conditions":"Hematologic Neoplasms","enrollment":320},{"nctId":"NCT07349771","phase":"PHASE2","title":"Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-31","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":72},{"nctId":"NCT01652092","phase":"NA","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-09-04","conditions":"SCID, Omenn's Syndrome, Reticular Dysgenesis","enrollment":57},{"nctId":"NCT05942599","phase":"PHASE1","title":"Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Great Ormond Street Hospital for Children NHS Foundation Trust","startDate":"2023-07-21","conditions":"Relapsed Acute Myeloid Leukaemia","enrollment":10},{"nctId":"NCT06450353","phase":"","title":"Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-05-31","conditions":"Allogeneic Transplantation","enrollment":1200},{"nctId":"NCT05799079","phase":"PHASE2","title":"Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant","status":"TERMINATED","sponsor":"Sanjay Mohan","startDate":"2023-04-13","conditions":"Recurrent Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT01174108","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-12-10","conditions":"Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)","enrollment":120},{"nctId":"NCT02171104","phase":"PHASE2","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-07-10","conditions":"Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome","enrollment":149},{"nctId":"NCT02962661","phase":"PHASE1","title":"Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-18","conditions":"Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":72},{"nctId":"NCT06395220","phase":"","title":"Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Haematological Malignancy","enrollment":314},{"nctId":"NCT06138587","phase":"PHASE1","title":"Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-01-24","conditions":"Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid","enrollment":15},{"nctId":"NCT00959140","phase":"NA","title":"Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2014-10","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":20},{"nctId":"NCT03128034","phase":"PHASE1, PHASE2","title":"211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2017-10-24","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT01850888","phase":"NA","title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-12","conditions":"Relapsed Neuroblastoma, Metastatic Pheochromocytoma","enrollment":15},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT06447987","phase":"PHASE1","title":"Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-11-06","conditions":"Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT01852370","phase":"PHASE1, PHASE2","title":"Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases","status":"ENROLLING_BY_INVITATION","sponsor":"Paul Szabolcs","startDate":"2013-06-20","conditions":"Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified, Severe Chronic Neutropenia","enrollment":16},{"nctId":"NCT01349101","phase":"PHASE2","title":"A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-02-10","conditions":"Hematological Malignancies","enrollment":78},{"nctId":"NCT01962415","phase":"PHASE2","title":"Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2014-02-04","conditions":"Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)","enrollment":100},{"nctId":"NCT05918055","phase":"PHASE1, PHASE2","title":"Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-14","conditions":"Myelodysplastic Syndromes","enrollment":3},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":488},{"nctId":"NCT02194868","phase":"","title":"Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-02-02","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies","enrollment":57},{"nctId":"NCT03326921","phase":"PHASE1","title":"HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-02-23","conditions":"Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia","enrollment":24},{"nctId":"NCT06735690","phase":"EARLY_PHASE1","title":"Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-06-09","conditions":"Acute Lymphoblastic Leukemia","enrollment":15},{"nctId":"NCT06928662","phase":"PHASE1, PHASE2","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-23","conditions":"Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia","enrollment":36},{"nctId":"NCT04263597","phase":"PHASE1, PHASE2","title":"Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2020-08-26","conditions":"Hematopoietic Stem Cell Transplant","enrollment":70},{"nctId":"NCT05236764","phase":"NA","title":"Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2023-12-06","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes","enrollment":3},{"nctId":"NCT02756962","phase":"PHASE2","title":"Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2016-07-06","conditions":"Acute Myeloid Leukemia","enrollment":107},{"nctId":"NCT04188678","phase":"","title":"Resiliency in Older Adults Undergoing Bone Marrow Transplant","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-09-28","conditions":"Leukemia, Lymphoma, Blood Cancer","enrollment":126},{"nctId":"NCT03670966","phase":"PHASE1, PHASE2","title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-07-10","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission","enrollment":30},{"nctId":"NCT03856216","phase":"PHASE2","title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-28","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm","enrollment":15},{"nctId":"NCT03779854","phase":"PHASE2","title":"Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-08-29","conditions":"Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":68},{"nctId":"NCT06529731","phase":"PHASE2","title":"Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Sawa Ito, MD","startDate":"2024-09-23","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":45},{"nctId":"NCT07210242","phase":"","title":"HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR","status":"NOT_YET_RECRUITING","sponsor":"Ting YANG","startDate":"2025-10-10","conditions":"Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Virus Reactivation","enrollment":300},{"nctId":"NCT07205523","phase":"","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","status":"RECRUITING","sponsor":"Yigeng Cao,MD,PhD","startDate":"2023-09-01","conditions":"Hematopoietic Stem Cell Transplantation (HSCT), Acute Myeloid Leukemia (AML), Leukemias, Acute Myeloid","enrollment":1000},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT05148234","phase":"PHASE1, PHASE2","title":"BMS-986253 in Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-29","conditions":"Myelodysplastic Syndromes","enrollment":2},{"nctId":"NCT02685098","phase":"PHASE1","title":"A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation","status":"COMPLETED","sponsor":"Indiana University","startDate":"2017-01-23","conditions":"Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease","enrollment":81},{"nctId":"NCT06668558","phase":"PHASE2","title":"Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias","startDate":"2024-12-16","conditions":"Acute Myeloid Leukemia","enrollment":29},{"nctId":"NCT05506956","phase":"PHASE1","title":"Post-transplant Flotetuzumab for AML","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-10-20","conditions":"Leukemia, Myeloid, Acute","enrollment":3},{"nctId":"NCT07157514","phase":"PHASE2, PHASE3","title":"Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2026-01","conditions":"Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":306}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6045,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Allogeneic bone marrow transplantation","genericName":"Allogeneic bone marrow transplantation","companyName":"Medical College of Wisconsin","companyId":"medical-college-of-wisconsin","modality":"Biologic","firstApprovalDate":"","aiSummary":"Allogeneic bone marrow transplantation involves transplanting bone marrow cells from a genetically non-identical donor to a recipient. This procedure is studied for various conditions, including Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome, using interventions such as Dilanubicel, Cyclophosphamide, and Fludarabine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}